Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
8Customers
2Debt Items
13Related Chains
Source-Backed Evidence Depth
Sagimet Biosciences Inc. (SGMT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
2Distinct source URLs
8High confidence
0.786Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Sagimet Biosciences Inc. Suppliers
Ticker
Name
Confidence
Evidence
ASCLETIS
ASCLETIS
85%
Ascletis granted us a non-exclusive, sublicensable, royalty-free license under certain intellectual property of Ascletis to develop, manufacture, and commercialize denifanstat and products containing…
ASSIA-CHEMICAL-INDUSTRIES-LTD
ASSIA-CHEMICAL-INDUSTRIES-LTD
85%
In September 2025, the Company entered into a term sheet with Assia Chemical Industries Ltd. (Assia), doing business as TAPI Technology & API Series (TAPI), a subsidiary of Teva Pharmaceutical Indust…
Sagimet Biosciences Inc. Customers
Ticker
Name
Confidence
Evidence
ASCLETIS-BIOSCIENCE-CO-LTD
ASCLETIS-BIOSCIENCE-CO-LTD
92%
The Company granted Ascletis and its affiliates an exclusive, royalty-bearing sublicensable right and license under the Company’s intellectual property to develop, manufacture, commercialize and othe…
ASCLETIS
ASCLETIS
90%
We are eligible to receive tiered royalty payments from Ascletis ranging from high single digit to mid-teen percentages on annual net sales of denifanstat and other products containing licensed compo…
TAPI-TECHNOLOGY-API-SERIES
TAPI-TECHNOLOGY-API-SERIES
90%
TAPI granted the Company a global, exclusive license to certain intellectual property rights covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient (API) for Sagimet’s techni…
ASSIA-CHEMICAL-INDUSTRIES-LTD
ASSIA-CHEMICAL-INDUSTRIES-LTD
62%
ion to develop, manufacture, and commercialize the Company’s proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted …
GANNEX-PHARMA-CO-LTD
GANNEX-PHARMA-CO-LTD
62%
ion to develop, manufacture, and commercialize the Company’s proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted …
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
oceeds from the sale of our redeemable convertible preferred stock and convertible notes. In August 2024, we entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to …
TEVA
Teva Pharmaceutical Industries Limited
62%
Reciprocal relationship from TEVA graph: Reciprocal relationship from SGMT graph: ion to develop, manufacture, and commercialize the Company’s proprietary FASN inhibitor, denifanstat, which Ascletis …
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD
TEVA-PHARMACEUTICAL-INDUSTRIES-LTD
62%
ion to develop, manufacture, and commercialize the Company’s proprietary FASN inhibitor, denifanstat, which Ascletis refers to as ASC40. Under the terms of the license agreement, the Company granted …
Sagimet Biosciences Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
SGMT-DEBT-12509
Warrants outstanding: -4000
90%
xbrl warrant detail from xbrl 2023-12-31.
SGMT-DEBT
Debt stack $39,000
90%
Market cache reports total debt of $39,000.
Sagimet Biosciences Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Sagimet Biosciences Inc..
Sagimet Biosciences Inc. Ownership
Holder
Name
Confidence
Evidence
SGMT-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 87 tracked holders.
Sagimet Biosciences Inc. Extended Supply Chain Network
